| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1295 | cd4409 | Novel agonist for the vitamin D receptor (VDR) |
|
| DCC1296 | cd4420 | Novel agonist for the vitamin D receptor (VDR) |
|
| DCC1297 | cd4528 | Novel agonist for the vitamin D receptor (VDR) |
|
| DCC1298 | Cddhqd-in-1 | Novel selective cdDHQD inhibitor |
|
| DCC1299 | Cdk12-in-7 | Novel potent and selective CDK12 inhibitor |
|
| DCC1300 | Cdk4 Inhibitor V | Potent, ATP-binding site-targeting Cdk4/D1 inhibitor |
|
| DCC1301 | Cdk6 Degrader Cp-10 | Novel potent CDK6 degrader |
|
| DCC1302 | Cdk6/pim1 Inhibitor 51 | Novel potent and balanced dual CDK6/PIM1 inhibitor, showing high kinase selectivity and displaying stronger potency in reducing the burden of AML than palbociclib and SMI-4a in vivo |
|
| DCC1303 | Cdk8 Inhibitor W-34 | Novel potent CDK8 inhibitor |
|
| DCC1304 | Cdk8/19-in-51 | Novel potent and selective dual inhibitor of CDK8 and CDK19 |
|
| DCC1305 | Cdk8/19-in-52h | Potent dual inhibitor of CDK8/19, suppressing phosphorylated STAT1 in various cancer cells |
|
| DCC1306 | Cdk8-in-18 | Novel potent and selective inhibitor of CDK8, also modulating CDK19 |
|
| DCC1307 | Cdk8-in-3 | Novel inhibitor of CDK8 |
|
| DCC1308 | Cdk8-in-32 | Novel highly potent, selective, permeable CDK8 inhibitor |
|
| DCC1309 | Cdk8-in-4k | Novel potent and highly selective CDK8 inhibitor, with no apparent potential for time-dependent CYP3A4 inhibition |
|
| DCC1310 | Cdk8-in-i | Novel potent CDK8 inhibitor |
|
| DCC1311 | Cdk8-in-ii | Novel CDK8 inhibitor |
|
| DCC1312 | Cdk8-in-iii | Novel CDK8 inhibitor |
|
| DCC1313 | Cdk8-in-iv | Novel CDK8 inhibitor |
|
| DCC1314 | Cdk9 Degrader 45 | Novel Potent and Selective CDK9 Degrader for Targeting Transcription Regulation in Triple-Negative Breast Cancer |
|
| DCC1315 | Cdk9/bet-in-40 | Novel potent dual inhibitor of CDK9 and BET proteins with balanced activities of BRD4 (IC50 = 12.7 nM) and CDK9 (IC50 = 22.4 nM), as well as good antiproliferative activities on a small cancer cell panel |
|
| DCC1316 | Cdk9/cyct1-in-93 | Highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity |
|
| DCC1317 | Cdk9-in-37 | Novel inhibitor of the cyclin-dependent kinase 9 (CDK9) |
|
| DCC1318 | Cdki Hydrochloride | Potent and selective ATP competitiive inhibitor of cycB-CDK1, cycE-CDK2, and cycD1-CDK4 |
|
| DCC1319 | Cdk-in-4.35 | Novel potent inhibitor of cyclin-dependent kinases (CDKs) 2, 5, and 9, displaying activities across more than 60 cancer cell lines |
|
| DCC1320 | Cdk-probe-p12 | Novel photoaffinity probe for cyclin-dependent kinase (CDK) family |
|
| DCC1321 | Cdm-3032 | Novel anti-hepatitis B virus (HBV) agent |
|
| DCC1322 | Ce-157119 | Highly permeable non-Pglycoprotein substrate |
|
| DCC1323 | ceb-52 | Potent Antagonist for the Human Thyrotropin Receptor (TSHR) |
|
| DCC1324 | Ceefourin-2 | Novel highly selective inhibitor of multidrug resistance protein 4 (MRP4) |
|
